A detailed history of Bank Of America Corp transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 332,101 shares of MIRM stock, worth $13.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
332,101
Previous 312,613 6.23%
Holding current value
$13.6 Million
Previous $7.85 Million 44.6%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$23.57 - $34.85 $459,332 - $679,156
19,488 Added 6.23%
332,101 $11.4 Million
Q1 2024

May 15, 2024

BUY
$24.92 - $30.02 $4.03 Million - $4.86 Million
161,789 Added 107.27%
312,613 $7.85 Million
Q4 2023

Feb 14, 2024

BUY
$27.14 - $34.93 $1.79 Million - $2.31 Million
66,089 Added 77.99%
150,824 $4.45 Million
Q2 2023

Aug 14, 2023

SELL
$23.51 - $30.09 $496,719 - $635,741
-21,128 Reduced 19.96%
84,735 $2.19 Million
Q1 2023

May 12, 2023

SELL
$19.19 - $24.1 $1.56 Million - $1.96 Million
-81,518 Reduced 43.5%
105,863 $2.54 Million
Q4 2022

Feb 10, 2023

BUY
$17.59 - $23.83 $2.34 Million - $3.17 Million
133,139 Added 245.45%
187,381 $3.65 Million
Q3 2022

Nov 14, 2022

BUY
$19.98 - $29.44 $891,627 - $1.31 Million
44,626 Added 464.08%
54,242 $1.14 Million
Q2 2022

Aug 12, 2022

BUY
$18.42 - $27.5 $73,716 - $110,055
4,002 Added 71.29%
9,616 $187,000
Q1 2022

May 16, 2022

SELL
$15.5 - $23.93 $16,926 - $26,131
-1,092 Reduced 16.28%
5,614 $124,000
Q4 2021

Feb 08, 2022

BUY
$13.05 - $19.35 $44,252 - $65,615
3,391 Added 102.29%
6,706 $107,000
Q3 2021

Nov 15, 2021

BUY
$13.95 - $20.18 $8,314 - $12,027
596 Added 21.92%
3,315 $66,000
Q2 2021

Sep 13, 2021

BUY
$15.84 - $20.6 $43,068 - $56,011
2,719 New
2,719 $47,000

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.51B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.